Végran F - Search Results

1

Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma.

Végran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S. Végran F, et al. PLoS One. 2013;8(1):e55103. doi: 10.1371/journal.pone.0055103. Epub 2013 Jan 24. PLoS One. 2013. PMID: 23359294 Free PMC article.

2

Distinct expression of Survivin splice variants in breast carcinomas.

Vegran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. Vegran F, et al. Int J Oncol. 2005 Oct;27(4):1151-7. Int J Oncol. 2005. PMID: 16142334

3

Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer.

Végran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. Végran F, et al. Oncogene. 2007 Jan 11;26(2):290-7. doi: 10.1038/sj.onc.1209784. Epub 2006 Jul 17. Oncogene. 2007. PMID: 16847456

4

Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy.

Végran F, Boidot R, Oudin C, Riedinger JM, Bonnetain F, Lizard-Nacol S. Végran F, et al. Clin Cancer Res. 2006 Oct 1;12(19):5794-800. doi: 10.1158/1078-0432.CCR-06-0725. Clin Cancer Res. 2006. PMID: 17020986

5

Patterns of loss of heterozygosity in breast carcinoma during neoadjuvant chemotherapy.

Oudin C, Bonnetain F, Boidot R, Végran F, Soubeyrand MS, Arnould L, Riedinger JM, Lizard-Nacol S. Oudin C, et al. Among authors: vegran f. Int J Oncol. 2007 May;30(5):1145-51. Int J Oncol. 2007. PMID: 17390016

6

The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas.

Boidot R, Vegran F, Jacob D, Chevrier S, Gangneux N, Taboureau J, Oudin C, Rainville V, Mercier L, Lizard-Nacol S. Boidot R, et al. Among authors: vegran f. Genes Chromosomes Cancer. 2008 Apr;47(4):299-308. doi: 10.1002/gcc.20533. Genes Chromosomes Cancer. 2008. PMID: 18181175

7

Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy.

Boidot R, Vegran F, Lizard-Nacol S. Boidot R, et al. Among authors: vegran f. Int J Mol Med. 2009 Feb;23(2):285-91. Int J Mol Med. 2009. PMID: 19148555

8

Variations in gene expression and response to neoadjuvant chemotherapy in breast carcinoma.

Boidot R, Vegran F, Soubeyrand MS, Fumoleau P, Coudert B, Lizard-Nacol S. Boidot R, et al. Among authors: vegran f. Cancer Invest. 2009 Jun;27(5):521-8. doi: 10.1080/07357900802298096. Cancer Invest. 2009. PMID: 19479487 Clinical Trial.

9

Gene expression profile and response to trastuzumab-docetaxel-based treatment in breast carcinoma.

Végran F, Boidot R, Coudert B, Fumoleau P, Arnould L, Garnier J, Causeret S, Fraise J, Dembélé D, Lizard-Nacol S. Végran F, et al. Br J Cancer. 2009 Oct 20;101(8):1357-64. doi: 10.1038/sj.bjc.6605310. Epub 2009 Sep 15. Br J Cancer. 2009. PMID: 19755993 Free PMC article.

10

The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism.

Boidot R, Végran F, Jacob D, Chevrier S, Cadouot M, Feron O, Solary E, Lizard-Nacol S. Boidot R, et al. Among authors: vegran f. Oncogene. 2010 Apr 29;29(17):2577-84. doi: 10.1038/onc.2009.525. Epub 2010 Jan 25. Oncogene. 2010. PMID: 20101202

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results